Switch to:
Also traded in: Australia, Germany, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt No Debt
GENE's Cash-to-Debt is ranked higher than
100% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.04 vs. GENE: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
GENE' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.13  Med: 45.1 Max: No Debt
Current: No Debt
Interest Coverage No Debt
GENE's Interest Coverage is ranked lower than
99.99% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.49 vs. GENE: No Debt )
Ranked among companies with meaningful Interest Coverage only.
GENE' s Interest Coverage Range Over the Past 10 Years
Min: 11.78  Med: 11.78 Max: No Debt
Current: No Debt
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
3-Year Revenue Growth Rate -61.80
GENE's 3-Year Revenue Growth Rate is ranked lower than
95% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. GENE: -61.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
GENE' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -2.2 Max: 39.5
Current: -61.8
0
39.5
3-Year EBITDA Growth Rate -35.90
GENE's 3-Year EBITDA Growth Rate is ranked lower than
91% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. GENE: -35.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
GENE' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0.9 Max: 31
Current: -35.9
0
31
3-Year EPS without NRI Growth Rate -37.00
GENE's 3-Year EPS without NRI Growth Rate is ranked lower than
86% of the 124 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.70 vs. GENE: -37.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
GENE' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -14.7 Max: 27.7
Current: -37
0
27.7
GuruFocus has detected 3 Warning Signs with Genetic Technologies Ltd $GENE.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» GENE's 30-Y Financials

Financials (Next Earnings Date: 2017-08-30 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

GENE Guru Trades in Q2 2016

Jim Simons 403,480 sh (+28.34%)
» More
Q3 2016

GENE Guru Trades in Q3 2016

Jim Simons 486,680 sh (+20.62%)
» More
Q4 2016

GENE Guru Trades in Q4 2016

Jim Simons 679,080 sh (+39.53%)
» More
Q1 2017

GENE Guru Trades in Q1 2017

Jim Simons 837,380 sh (+23.31%)
» More
» Details

Insider Trades

Latest Guru Trades with GENE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 325414    SIC: 2836
Compare:NAS:CBMX, OTCPK:MYAN, NAS:BIOP, OTCPK:GNWSF, OTCPK:TDSGF, NAS:IDXG, NAS:ROKA, OTCPK:MNLIF, NAS:OPGN, OTCPK:LXXGF, OTCPK:ILIU, NAS:BASI, OTCPK:MHTX, NAS:CDNA, OTCPK:CRRVF, NAS:TEAR, NAS:TROV, OTCPK:MDIT, NAS:DRIO, OTCPK:TDLAF » details
Traded in other countries:GTG.Australia, DU8.Germany, GNTLF.USA,
Headquarter Location:Australia
Genetic Technologies Ltd is a molecular diagnostics company. It offers predictive testing and assessment tools to help physicians manage women's health.

Genetic Technologies Ltd is incorporated in Australia on January 05, 1987. The Company is a biotechnology company focused on expanding genetic testing business in the Asia-Pacific region and, with the addition of the BREVAGenTM breast cancer risk assessment test, in the U.S.A. and later in Europe. In addition, it is now pursuing commercial opportunities in other areas of activity: out-licensing non-coding patents; and supporting a late-stage research and development project in which it is already involved. The patents in the portfolio includes ntron Sequence Analysis; Genomic Mapping; Perlegen; BREVAGenTM; Laboratory Techniques; Ancestral Haplotypes; Athletic Performance;Nematode Project; and RareCellect Project.

Top Ranked Articles about Genetic Technologies Ltd

Genetic Technologies and Verizon IndyCar Series Driver Pippa Mann Update BREVAGenplus(R) Marketing Partnership

MELBOURNE, AUSTRALIA--(Marketwired - Jun 22, 2016) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company"), a molecular diagnostics company specializing in women's health, and provider of BREVAGenplus®, a first-in-class, clinically validated risk assessment test for sporadic breast cancer, announced today an update on its marketing partnership with Verizon IndyCar Series driver, Pippa Mann. The program commenced with the Indianapolis 500, the largest single day sporting event in the world, in terms of on-site attendance. The event offered significant promotional opportunities throughout the month of May, leading-up to the historic 100th running of the race, which took place on May 29, 2016. Mann is one of only nine female athletes to ever compete in the Indianapolis 500 and the only female driver to start in the race over the past four consecutive years. The BREVAGenplus logo was featured on Mann's #63 Dale Coyne Racing Indy Car supporting Susan G. Komen, the world's largest breast cancer organization, as well as being prominently placed on her racing and promotional apparel. Mann was featured in BREVAGenplus advertising that appeared in the official Indy 500 Program and also in the USA Today special commemorative edition about the race. Mann also participated in a variety of BREVAGenplus promotional activities leading-up to the race at the Indianapolis Motor Speedway, hosted a breast cancer survivor event and promoted BREVAGenplus at public appearances and on her social media platforms. Additional promotional events that occurred in May with Mann included joining Eutillio Buccilli, Chief Executive Officer of Genetic Technologies Limited at the Nasdaq MarketSite in New York City's Times Square to perform the honorary ringing of the Closing Bell. Whilst in New York, Mann also participated in a media tour, appearing on CNBC Television's "Squawk Box," along with Fox Sports Business, Sirius XM Radio and conducting interviews with Glamour Magazine and Forbes Business Online reporters. Please visit our website to view our recent news and media appearances. "We were extremely pleased to be invited to Nasdaq's MarketSite for the ceremonial bell ringing at this exciting time for the Company as we continue to ramp-up commercial activities for BREVAGenplus," commented Buccilli. "The event had additional meaning to us as it ceremoniously marked, in earnest, the beginning of our partnership with Pippa Mann, a next generation athlete who has demonstrated true conviction and commitment to promoting women's health and in particular, breast cancer awareness." "It was exciting to kick off my association with Genetic Technologies by going to New York and ringing the closing bell on behalf of the Company," said Mann. "I'm pleased they've chosen me to help promote BREVAGenplus as I believe the test can have a valuable impact on proactively managing women's health, which is near and dear to my heart." Moving forward, the BREVAGenplus logo will continue to be featured on Mann's racing and promotional apparel, and she will appear in the Company's promotional print, video and social media platforms, promoting BREVAGenplus and its role in her overall advocacy for women's wellness. As a lead-up to October's Breast Cancer Awareness Month, the back half of calendar year 2016 will feature many appearances by Mann including Fox Sports TV Channels throughout the United States this summer, The Susan G. Komen 2016 Partner Summit in New York City in late June, and Susan G. Komen Race for the Cure events across the U.S. About Genetic Technologies Limited

Genetic Technologies is a molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The Company's lead product, BREVAGenplus®, is a clinically validated risk assessment test for non-hereditary breast cancer and is first in its class. BREVAGenplus improves upon the predictive power of the first generation BREVAGen test and is designed to facilitate better informed decisions about breast cancer screening and preventive treatment plans. BREVAGenplus expands the application of BREVAGen from Caucasian women to include African-Americans and Hispanics, and is directed towards women aged 35 years or above, who have not had breast cancer and have one or more risk factors for developing breast cancer. The Company has successfully launched the first generation BREVAGen test across the U.S. via its U.S. subsidiary Phenogen Sciences Inc. and the addition of BREVAGenplus, launched in October 2014, significantly expands the applicable market. The Company markets BREVAGenplus to healthcare professionals in comprehensive breast health care and imaging centres, as well as to obstetricians/gynaecologists (OBGYNs) and breast cancer risk assessment specialists (such as breast surgeons). For more information, please visit www.brevagenplus.com and www.phenogensciences.com. About Pippa Mann

Having grown up as a race fan, Pippa Mann began her motorsport career in Europe, before moving to the States in 2009 to compete in the Firestone Indy Lights Series. There she became the first female in history to win a pole at the Indianapolis Motor Speedway, and only the second woman ever to win an Indy Lights race. In 2011, Mann became the eighth woman in history to qualify for and race in the Indianapolis 500, and the first British female to do so. Mann has now competed in four Indianapolis 500 races, and is currently the second fastest female qualifier of all time with a four lap average of the Speedway at just under 230mph. Outside of the car Mann is passionate about her partnership with Susan G. Komen®, and about her role as a Wellness Ambassador for Well & Company. She regularly spends time connecting with her fan-base directly through social media interaction, in person appearances and autograph signings, and she strives to inspire young girls to believe in themselves and follow their dreams. Visit www.pippamann.com to learn more. About Dale Coyne Racing

Dale Coyne Racing (DCR) is a Verizon IndyCar Series team based in Plainfield, IL, about 40 miles southwest of downtown Chicago. The team has participated in every season of the INDYCAR/Champ Car World Series since 1984, making this their 32nd season of competition. DCR earned its third IndyCar win with a victory in Detroit in 2013 where they finished with both cars on the podium. The team was able to win for a fourth straight season in 2014 when visiting victory lane in Houston. Team Owner Dale Coyne is a true racer with a long history in racing. As an Indy car driver for five years, and a team owner since 1984, he has more than 30 years of experience in open-wheel racing. Coyne is a Midwestern entrepreneur who designed and built Route 66 Raceway in Joliet, IL. Dale Coyne and Tony George, along with International Speedway Corporation (ISC), expanded the facility by forming a partnership and building Chicagoland Speedway. Coyne served as president of the facility through its construction and opening season, and served on its management committee until its eventual buyout by ISC in 2007. Safe Harbor Statement

Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with Genetic Technologies' business can be found in its periodic filings with the SEC.


FOR FURTHER INFORMATION PLEASE CONTACT

Mr. Eutillio Buccilli

Executive Director & Chief Executive Officer

Genetic Technologies Limited

61 3 8412 7050


Candice Knoll (USA)

Blueprint Life Science Group

1 (415) 375 3340, Ext. 4





Read more...
Genetic Technologies Announces Appointment of Senior Medical Director

MELBOURNE, AUSTRALIA--(Marketwired - Jun 21, 2016) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company"), a molecular diagnostics company specializing in women's health, and provider of BREVAGenplus®, a first-in-class, clinically validated risk assessment test for sporadic breast cancer, is pleased to announce the appointment of Dr. Susan J. Gross, MD, FRCSC, FACOG, FACMG as Senior Medical Director, effective 20 June 2016. Dr. Gross received her medical degree from the University of Toronto, Ontario, Canada, where she completed her residency in Obstetrics and Gynecology, as well as a fellowship in Maternal Fetal Medicine and a second residency/fellowship in Medical Genetics at the University of Tennessee (Memphis). She is board certified in both Obstetrics and Gynecology and Medical Genetics and is a Professor of Clinical Obstetrics & Gynecology, Women's Health, Pediatrics and Genetics at the Albert Einstein College of Medicine. She served as past division director for the Division of Reproductive Genetics at Montefiore Medical Center as well as Chairperson of the Department of Obstetrics and Gynecology and founder of the Human Genetics Laboratory at Jacobi Medical Center. Dr. Gross has spent decades not only in research and medical education, but also direct patient care, overseeing both large and small practice systems. She has worked on national and international guideline committees and lectured and published extensively on screening and genetic testing with a focus on new technologies and public health policy. She was previously the Chief Medical Officer of Natera Inc., a public genomic diagnostics company and is now President of SJG Advisors LLC, a company that provides comprehensive medical affairs and digital media expertise to the diagnostics industry. Genetic Technologies' Chief Executive Officer Mr. Eutillio Buccilli commented on the appointment saying: "The addition of Dr. Gross to the Company's Executive Team, adds a level of knowledge and experience that will be invaluable as the Company looks to build on the significant momentum generated so far in fiscal year 2016, and executes on its strategy to expand the reach of its lead breast cancer risk assessment test BREVAGenplus, across the U.S." About Genetic Technologies Limited

Genetic Technologies is a molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The Company's lead product, BREVAGenplus®, is a clinically validated risk assessment test for non-hereditary breast cancer and is first in its class. BREVAGenplus improves upon the predictive power of the first generation BREVAGen test and is designed to facilitate better informed decisions about breast cancer screening and preventive treatment plans. BREVAGenplus expands the application of BREVAGen from Caucasian women to include African-Americans and Hispanics, and is directed towards women aged 35 years or above, who have not had breast cancer and have one or more risk factors for developing breast cancer. The Company has successfully launched the first generation BREVAGen test across the U.S. via its U.S. subsidiary Phenogen Sciences Inc. and the addition of BREVAGenplus, launched in October 2014, significantly expands the applicable market. The Company markets BREVAGenplus to healthcare professionals in comprehensive breast health care and imaging centres, as well as to obstetricians/gynaecologists (OBGYNs) and breast cancer risk assessment specialists (such as breast surgeons). For more information, please visit www.brevagenplus.com and www.phenogensciences.com. Safe Harbor Statement

Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with Genetic Technologies' business can be found in its periodic filings with the SEC.


FOR FURTHER INFORMATION PLEASE CONTACT

Mr. Eutillio Buccilli

Executive Director & Chief Executive Officer

Genetic Technologies Limited

61 3 8412 7050


Candice Knoll (USA)

Blueprint Life Science Group

1 (415) 375 3340, Ext. 4





Read more...

Ratios

vs
industry
vs
history
PB Ratio 1.11
GENE's PB Ratio is ranked higher than
92% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.69 vs. GENE: 1.11 )
Ranked among companies with meaningful PB Ratio only.
GENE' s PB Ratio Range Over the Past 10 Years
Min: 0.21  Med: 1.04 Max: 7.2
Current: 1.11
0.21
7.2
EV-to-EBIT -1.64
GENE's EV-to-EBIT is ranked lower than
99.99% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.08 vs. GENE: -1.64 )
Ranked among companies with meaningful EV-to-EBIT only.
GENE' s EV-to-EBIT Range Over the Past 10 Years
Min: -554.2  Med: -43.5 Max: 29.5
Current: -1.64
-554.2
29.5
EV-to-EBITDA -1.72
GENE's EV-to-EBITDA is ranked lower than
99.99% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.34 vs. GENE: -1.72 )
Ranked among companies with meaningful EV-to-EBITDA only.
GENE' s EV-to-EBITDA Range Over the Past 10 Years
Min: -591.7  Med: 5.4 Max: 117.6
Current: -1.72
-591.7
117.6
Current Ratio 9.11
GENE's Current Ratio is ranked higher than
90% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. GENE: 9.11 )
Ranked among companies with meaningful Current Ratio only.
GENE' s Current Ratio Range Over the Past 10 Years
Min: 1.08  Med: 3.87 Max: 11.28
Current: 9.11
1.08
11.28
Quick Ratio 9.11
GENE's Quick Ratio is ranked higher than
91% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. GENE: 9.11 )
Ranked among companies with meaningful Quick Ratio only.
GENE' s Quick Ratio Range Over the Past 10 Years
Min: 1.04  Med: 3.17 Max: 11.09
Current: 9.11
1.04
11.09

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -53.40
GENE's 3-Year Average Share Buyback Ratio is ranked lower than
87% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.00 vs. GENE: -53.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GENE' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -54.5  Med: -7.2 Max: 0
Current: -53.4
-54.5
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 1.00
GENE's Price-to-Net-Cash is ranked higher than
99% of the 72 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.15 vs. GENE: 1.00 )
Ranked among companies with meaningful Price-to-Net-Cash only.
GENE' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1  Med: 11.33 Max: 50
Current: 1
1
50
Price-to-Net-Current-Asset-Value 1.00
GENE's Price-to-Net-Current-Asset-Value is ranked higher than
97% of the 122 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.79 vs. GENE: 1.00 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
GENE' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1  Med: 6 Max: 50
Current: 1
1
50
Price-to-Tangible-Book 1.00
GENE's Price-to-Tangible-Book is ranked higher than
95% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.28 vs. GENE: 1.00 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
GENE' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1  Med: 8.78 Max: 40
Current: 1
1
40
Earnings Yield (Greenblatt) % -60.94
GENE's Earnings Yield (Greenblatt) % is ranked lower than
99.99% of the 297 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.45 vs. GENE: -60.94 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
GENE' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -60.98  Med: 8.9 Max: 8.9
Current: -60.94
-60.98
8.9

More Statistics

Revenue (TTM) (Mil) $0.62
EPS (TTM) $ -0.51
Beta3.45
Short Percentage of Float0.00%
52-Week Range $1.04 - 2.89
Shares Outstanding (Mil)16.24
» More Articles for GENE

Headlines

Articles On GuruFocus.com
Genetic Technologies Launches BREVAGenplus(R) Marketing Program Around Susan G. Komen(R)'s Race for Oct 03 2016 
Genetic Technologies and Verizon IndyCar Series Driver Pippa Mann Update BREVAGenplus(R) Marketing P Jun 22 2016 
Genetic Technologies Announces Appointment of Senior Medical Director Jun 21 2016 
Genetic Technologies and Verizon IndyCar Series Driver Pippa Mann to Ring Nasdaq Stock Market Closin May 04 2016 
Genetic Technologies and IndyCar's Pippa Mann Announce Partnership to Promote BREVAGenplus(R) Feb 22 2016 
Genetic Technologies Announces Publication of Key Scientific Validation Results in Support of BREVAG Dec 21 2015 
Genetic Technologies Granted Key Patents by US Patent Office for BREVAGenplus(R) Aug 06 2015 
Genetic Technologies Announces Scientific Validation, Clinical Trial and Peer Review Publication Ini Jul 14 2015 
Genetic Technologies Appoints Eutillio Buccilli as Chief Executive Officer Feb 26 2015 
Clinical Validation Study Supporting the Use of BREVAGenplus(R) in Breast Cancer Risk Assessment Dec 17 2014 

More From Other Websites
Genetic Technologies Revamps Patient Pricing and Billing Program for BREVAGenplus(R) Mar 31 2017
Genetic Technologies and IndyCar's Pippa Mann Partner for Second Consecutive Year to Promote... Mar 29 2017
Genetic Technologies Ltd. :GENE-US: Earnings Analysis: For the six months ended December 31, 2016 :... Feb 24 2017
Genetic Technologies Announces Offering of USD 6.0 Million of American Depository Shares Dec 01 2016
Genetic Technologies Limited and The University of Melbourne Enter into Exclusive Worldwide License... Nov 29 2016
Genetic Technologies Launches BREVAGenplus(R) Marketing Program Around Susan G. Komen(R)'s Race for... Oct 03 2016
Genetic Technologies and Verizon IndyCar Series Driver Pippa Mann Update BREVAGenplus(R) Marketing... Jun 22 2016
Genetic Technologies Announces Appointment of Senior Medical Director Jun 21 2016
Genetic Technologies and Verizon IndyCar Series Driver Pippa Mann to Ring Nasdaq Stock Market... May 04 2016
Four Trending Stocks That Require Your Attention on April 15th Apr 15 2016
Genetic Technologies and IndyCar's Pippa Mann Announce Partnership to Promote BREVAGenplus(R) Feb 22 2016
The Top 5 Penny Stocks for 2016 (CRIS, AG) Jan 04 2016
What Stands Behind These Stocks’ Bullish Moves Today? Dec 21 2015
4 Stocks Trading With Heavy Volume Today Dec 21 2015
Genetic Technologies Announces Publication of Key Scientific Validation Results in Support of... Dec 21 2015
4 Stocks Heading Into Thanksgiving On A High Note Nov 25 2015
Biotech Sector Due Diligence Report Highlights 4 Emerging Companies - Broad Street Alerts Nov 24 2015
Why US manufacturers are taking jobs to China Sep 21 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat